RxDoctor Payments Data

Christopher Petrus, MD

Urology · Fairhope, ALNPI 1982667622

Payments from drug & device makers

$6,833in general payments, 2019–2025

Across 308 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$720
  • Johnson & Johnson$628
  • AbbVie$616
  • Sumitomo Pharma America, Inc.$414
  • Endo Pharmaceuticals Inc.$377
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$94214%
  • Food & beverage$5,68683%
  • Education$2063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,833 in reported general payments places this provider in the 65th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$213,579
Medicare patients
576
Services billed
8,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide13$194,130
MyrbetriqMirabegron142$88,513
GemtesaVibegron80$47,470
Trimethoprim146$11,362
Tamsulosin Hcl521$9,122
Finasteride490$6,812
Testosterone13$5,408
Oxybutynin Chloride ErOxybutynin Chloride197$5,339
Testosterone Cypionate112$4,692
Tolterodine Tartrate ErTolterodine Tartrate48$4,531
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst95$4,435
Methenamine Hippurate37$3,740
Alfuzosin Hcl ErAlfuzosin Hcl154$3,696
Potassium Citrate ErPotassium Citrate41$3,580
Tadalafil25$2,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$628$194,13013 claims
Astellas Pharma US IncMyrbetriq$720$88,513142 claims
Sumitomo Pharma America, Inc.Gemtesa$414$47,47080 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 179 urology providers in Alabama.

Other urology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →